+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Final overall survival results and effect of prolonged ?1 year first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial



Final overall survival results and effect of prolonged ?1 year first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial







The ATHENA study expanded on the safety and efficacy data derived from first-line trials of bevacizumab combined with standard chemotherapy for locally recurrent/metastatic breast cancer (LR/mBC). In ATHENA, 2,264 patients received first-line bevacizumab-containing therapy in routine oncology practice. Overall survival (OS) data are now mature; additional analyses from this large data set can provide insights into treatment duration and the effect of prolonged bevacizumab exposure, where data are currently limited. Patients with HER2-negative LR/mBC received first-line bevacizumab with standard chemotherapy until disease progression, unacceptable toxicity, or physician/patient decision. We performed subgroup analyses on data from patients treated for ?12 months and those who continued single-agent bevacizumab after stopping chemotherapy. After median follow-up of 2.1 months, median OS was 25.2 months (95% confidence interval 24. 26.3 months) in the entire population. Median OS was 3. months (95% CI 28.5 32.7 months) in 1,25 patients who continued bevacizumab after discontinuation of chemotherapy and 18.4 months (95% CI 17.2 19.7 months) in 1,58 patients who discontinued bevacizumab before or at the same time as stopping chemotherapy. Bevacizumab treatment was continued for ?12 months in 473 patients (21%). In most, bevacizumab was administered as monotherapy for extended periods after stopping chemotherapy. In the subgroup of patients treated for ?12 months, the median time to onset of grade 3 5 adverse events was 5. months. There was no evidence that first onset of adverse events of special interest, except for proteinuria, was more common in later than earlier cycles. No relationship was detected between development of hypertension and OS. Findings from these analyses suggest that patients with LR/mBC can receive bevacizumab for prolonged periods without major toxicity or progression of disease. In the absence of progression, continuation of single-agent bevacizumab appears to be a reasonable approach, with minimal toxicity and the possibility of long-term disease control.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 036176601

Download citation: RISBibTeXText


Related references

Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial. Breast Cancer Research and Treatment 130(1): 133-143, 2011

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. Annals of Oncology 27(11): 2046-2052, 2016

Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer : overall survival and subgroup analyses of the ATHENA study in France. Bulletin du Cancer 101(9): 780-788, 2014

First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study. Anticancer Research 36(3): 967-974, 2016

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Annals of Oncology 26(4): 724-730, 2015

Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Clinical and Translational Oncology 17(2): 160-166, 2015

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment 123(2): 427-435, 2010

First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study. Annals of Oncology 23(1): 111-118, 2012

Final results for overall survival (Os), the primary endpoint of the Cecog Turandot prospective randomised trial evaluating bevacizumab-paclitaxel (Bev-Pac) vs Bev-capecitabine (Cap) for Her2-negative locally recurrent/metastatic breast cancer (Lr/mBc). European Journal of Cancer 51: S263-S264, 2015

Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study. Chinese Medical Journal 125(5): 764-769, 2012

A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study. Annals of Oncology 27(6): 1020-1029, 2016

Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France. Bulletin du Cancer 99(6): 609-618, 2012

Promising activity and safety of exemestane as first-line hormonal therapy in metastatic breast cancer patients Final results of an EORTC Randomised Phase II trial. Breast Cancer Research & Treatment 64(1): 52, 2000

Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Annals of Oncology 26(6): 1201-1207, 2015

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet. Oncology 14(2): 125-133, 2013